ReviewNature reviews. Clinical oncology2013
Biopsies: next-generation biospecimens for tailoring therapy.
Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Trial
- Prospective Randomized Trial for Image-Guided Biopsy Using Cone-Beam CT Navigation Compared with Conventional CT.Journal of vascular and interventional radiology : JVIR · 2016Trial
- Artificial intelligence in small tissue biopsies: diagnostic applications, histochemical integration, and methodological challenges in surgical pathology.Histochemistry and cell biology · 2026Review
- From Hematoxylin and Eosin to Masson's Trichrome: A Comprehensive Framework for Virtual Stain Transformation in Chronic Liver Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- The role of ROSE-enhanced ERCP-guided biopsy in diagnosing biliary stricture.Scientific reports · 2025Article
- Bridging laboratory innovation to translational research and commercialization of extracellular vesicle isolation and detection.Biosensors & bioelectronics · 2025Review
- Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care.Breast cancer research : BCR · 2025Review
- Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing.Bioactive materials · 2025Article
- Validating the predictions of mathematical models describing tumor growth and treatment response.ArXiv · 2025Article
- Liquid biopsy in cancer management: Integrating diagnostics and clinical applications.Practical laboratory medicine · 2025Review
- Core Needle Biopsy Guidance Based on Tissue Morphology Assessment with AI-OCT Imaging.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Ultrasound-guided biopsy of challenging abdominopelvic targets.Abdominal radiology (New York) · 2022Review
- Article
- Bleeding management in computed tomography-guided liver biopsies by biopsy tract plugging with gelatin sponge slurry.Scientific reports · 2021Article
- Synchronized Tissue Acquisition Techniques for Novel Biomarker Discovery: Are You Ready to Waltz?Journal of immunotherapy and precision oncology · 2021Article
- Basic principles of biobanking: from biological samples to precision medicine for patients.Virchows Archiv : an international journal of pathology · 2021Review
- Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021Review
- Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.Clinical and translational medicine · 2021Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of samples in existing tumour biobanks are surgical specimens of primary tumours. Insights into tumour biology, such as intratumoural heterogeneity, tumour-host crosstalk, and the evolution of the disease during therapy, require biospecimens from the primary tumour and those that reflect the patient's disease in specific contexts. Next-generation 'omics' technologies facilitate deep interrogation of tumours, but the characteristics of the samples can determine the ultimate accuracy of the results. The challenge is to biopsy tumours, in some cases serially over time, ensuring that the samples are representative, viable, and adequate both in quantity and quality for subsequent molecular applications. The collection of next-generation biospecimens, tumours, and blood samples at defined time points during the disease trajectory--either for discovery research or to guide clinical decisions--presents additional challenges and opportunities. From an organizational perspective, it also requires new additions to the multidisciplinary therapeutic team, notably interventional radiologists, molecular pathologists, and bioinformaticians. In this Review, we describe the existing procedures for sample procurement and processing of next-generation biospecimens, and highlight the issues involved in this endeavour, including the ethical, logistical, scientific, informational, and financial challenges accompanying next-generation biobanking.
Indexed as
Identifiers
23799370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.